BFLY · Butterfly Network, Inc.

Current Thesis

Butterfly Network's ultrasound-chip licensing thesis requires third-quarter revenue confirmation and a weekly recovery above $8.84 before a weekly close below $7.00 breaks the case. The September 18 adjusted close of $7.88 improves on September 10's $7.12, but remains below the August 14 reference close of $8.84. The defined success condition remains that price recovery by the third-quarter report, accompanied by revenue meeting guidance.

A material correction concerns government certification: the Federal Risk and Authorization Management Program (FedRAMP) marketplace records Butterfly as certified since 2026-08-26. September 30 is therefore no longer a pending certification deadline; certification has occurred, although the registry supplies no revenue evidence. Federal certification record.

As of 2026-09-20, the narrative is maturing — the September 1 Merge Labs agreement extended the licensing story, while September 18's close still trails August's reference. This is an inference from announcements and price structure, not a measurement of investor participation. Revenue confirmation and a weekly close above $8.84 would challenge that classification.

Bullish and bearish views on Butterfly Network, Inc.

The model's bull view on Butterfly Network, Inc. (BFLY), in brief: Licensing reaches another application. Butterfly announced its multi-year Merge Labs agreement on 2026-09-01, providing ultrasound-chip access for brain-computer interface development. The announcement identifies a commercial relationship but discloses no aggregate contract… The bear view: Guidance permits sequential contraction. Both cases follow in full.

Bull Case

• Licensing reaches another application. Butterfly announced its multi-year Merge Labs agreement on 2026-09-01, providing ultrasound-chip access for brain-computer interface development. The announcement identifies a commercial relationship but discloses no aggregate contract value. Company announcement.
• Government certification is completed. The federal marketplace dates certification to 2026-08-26. This resolves the certification milestone previously treated as pending; subsequent government contracts and revenue remain separate tests. Federal certification record.
• Reported revenue supports commercial substance. Butterfly's 2026-07-30 release reported second-quarter revenue of $32.6 million, up 39% year over year, and attributed part of the growth to Embedded partnerships. That quarter alone cannot establish repeatable licensing growth. Second-quarter results.

Bear Case

• Guidance permits sequential contraction. The 2026-07-30 release guided third-quarter revenue to $26–30 million, below second-quarter revenue of $32.6 million. Meeting guidance would therefore confirm delivery against management's forecast without establishing sequential expansion. Company guidance.
• Partner economics remain unquantified. The 2026-09-01 Merge announcement supplies no aggregate contract value. Its contribution cannot be incorporated into a quantified revenue case from that announcement. Agreement announcement.

Setup & Price Structure

The adjusted daily series records a $7.88 close on 2026-09-18, a three-month price gain of 8.4%, and a close 18.8% below the trailing annual high of $9.70. The 14-day relative strength index (RSI) was 43.7. These are measured observations; they do not establish a completed reversal.

The September 11 published research identified $7.00 as the late-June breakout boundary and the August 14 close of $8.84 as the recovery threshold. September 18's close sits between those conditions. Its improvement from September 10 does not establish that every intervening weekly close preserved the boundary.

Benzinga records TD Cowen analyst Joshua Jennings maintaining a $10 price target on 2026-09-11. That is a third-party valuation opinion, not evidence that the market will reach it. Current short interest, moving-average values and systematic retail-coverage counts are missing, so crowding cannot be quantified. Dated analyst action.

Catalyst Calendar (next 30 days)

• 2026-10-01 — Planned care-service implementation. Management's 2026-07-30 call, as recorded in the September 11 coverage, identified this date for the first state Home & Community Care implementation. The written release expected initial revenue in the fourth quarter; a disclosed postponement would invalidate the scheduled launch assumption. Company business update.
• ~2026-10-29, est. Third-quarter results. This later event is the central financial test: revenue against the $26–30 million guidance issued on 2026-07-30. The reporting date remains an estimate, not a company-confirmed appointment. Company guidance.

What Would Change Our Mind

Loss of the late-June breakout structure ends the price thesis: a weekly close below $7.00 breaches the boundary retained in the September 11 research. Third-quarter revenue below the $26 million guidance floor would independently break the revenue-confirmation case. Failure to record a weekly close above the August 14 reference of $8.84 by the third-quarter report would leave the specified recovery outcome unmet.

The completed August 26 certification removes one pending execution risk, and September 18's higher close improves the price evidence. Together they support a modestly favorable probability assessment, but neither demonstrates repeatable licensing revenue.

Correlation Notes

The 2026-09-01 Merge agreement gives Butterfly exposure to brain-computer interface development, but establishes no measured stock-price correlation with other companies in that field. This remains a single-name licensing case. No matched peer-return series accompanies the September 18 observations; the evidence is insufficient to claim a sector-driven move.